studies

la/mBC - HER2 positive, ... vs. HER inhibitor, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsSYSUCC-002, 2022 (REV) 1.22 [0.96; 1.54] 1.22[0.96; 1.54]SYSUCC-002, 2022 (REV)10%392NAnot evaluable progression or deaths (PFS)detailed resultsSYSUCC-002, 2022 (REV) 1.14 [0.92; 1.41] 1.14[0.92; 1.41]SYSUCC-002, 2022 (REV)10%392NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-07-01 19:46 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 355,337,146,317 - treatments: 1305

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons